• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性中心性浆液性脉络膜视网膜病变患者脉络膜新生血管的 3 年随访。

Three-year follow-up of choroidal neovascularisation in eyes of chronic central serous chorioretinopathy.

机构信息

Ophthalmology, Changhua Christian Hospital, Changhua City, Taiwan.

Ophthalmology, Changhua Christian Hospital Yunlin Branch, Xiluo, Yunlin, Taiwan.

出版信息

Br J Ophthalmol. 2020 Nov;104(11):1561-1566. doi: 10.1136/bjophthalmol-2019-315302. Epub 2020 Feb 12.

DOI:10.1136/bjophthalmol-2019-315302
PMID:32051140
Abstract

AIMS

This study aimed to report the 3-year follow-up results of the clinical course and structural changes of choroidal neovascularisation (CNV) by optical coherence tomography angiography (OCT-A) in eyes with a history of chronic central serous chorioretinopathy (CSC).

METHODS

This is a retrospective study of patients with chronic CSC complicated with CNV. Patients were recorded of best-corrected visual acuity (BCVA) and treatment modalities. OCT was used to evaluate the presence of subretinal fluid (SRF), type of CNV, changes in central retinal thickness (CRT) and subfoveal choroidal thickness (SFCT). Changes in the size, vessel density (VD) and morphology of CNV were evaluated by OCT-A. Comparison between baseline and final parameters was made.

RESULTS

A total of 30 eyes in 26 patients, most of whom had previous treatment for chronic CSC, were included with a mean follow-up period of 40.37±4.11 months. No changes in BCVA were noted (p=0.562). During the 3-year follow-up period with OCT-A, five eyes had SRF noted. The other 25 eyes remained SRF free throughout the course. Regarding the morphological changes, the size of CNV enlarged significantly (p<0.01); VD of CNV decreased significantly (p=0.01); and the number of CNV with visible core vessel significantly increased (p<0.01). A significant reduced SFCT was noted (p=0.02), while the CRT remained unchanged (p=0.855).

CONCLUSION

For most eyes infected with chronic CSC receiving previous treatment for the activity of chronic CSC, with CNV subsequently found on OCT-A, a midterm stable clinical course up to 3 years was noted, despite significant structural changes of CNV evaluated by OCT-A.

摘要

目的

本研究旨在报告光学相干断层扫描血管造影(OCT-A)对既往有慢性中心性浆液性脉络膜视网膜病变(CSC)病史的脉络膜新生血管(CNV)患者的临床病程和结构变化的 3 年随访结果。

方法

这是一项回顾性研究,纳入了患有慢性 CSC 合并 CNV 的患者。记录了患者最佳矫正视力(BCVA)和治疗方式。使用 OCT 评估是否存在视网膜下液(SRF)、CNV 类型、中心视网膜厚度(CRT)和中心凹下脉络膜厚度(SFCT)的变化。通过 OCT-A 评估 CNV 的大小、血管密度(VD)和形态的变化。比较了基线和最终参数。

结果

共纳入 26 例患者的 30 只眼,大多数患者曾接受过慢性 CSC 的治疗,平均随访时间为 40.37±4.11 个月。BCVA 无变化(p=0.562)。在 3 年的 OCT-A 随访期间,有 5 只眼出现了 SRF。其余 25 只眼在整个病程中均无 SRF。在形态学变化方面,CNV 的大小显著增大(p<0.01);CNV 的 VD 显著降低(p=0.01);可见核心血管的 CNV 数量显著增加(p<0.01)。SFCT 显著降低(p=0.02),而 CRT 保持不变(p=0.855)。

结论

对于大多数既往接受过慢性 CSC 活动治疗、随后在 OCT-A 上发现 CNV 的慢性 CSC 感染眼,尽管 OCT-A 评估的 CNV 结构变化显著,但在 3 年内观察到中期稳定的临床病程。

相似文献

1
Three-year follow-up of choroidal neovascularisation in eyes of chronic central serous chorioretinopathy.慢性中心性浆液性脉络膜视网膜病变患者脉络膜新生血管的 3 年随访。
Br J Ophthalmol. 2020 Nov;104(11):1561-1566. doi: 10.1136/bjophthalmol-2019-315302. Epub 2020 Feb 12.
2
Predictors of treatment response to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for choroidal neovascularisation secondary to chronic central serous chorioretinopathy.预测慢性中心性浆液性脉络膜视网膜病变继发脉络膜新生血管对玻璃体内抗血管内皮生长因子(抗 VEGF)治疗的反应的因素。
Br J Ophthalmol. 2020 Jul;104(7):910-916. doi: 10.1136/bjophthalmol-2019-314625. Epub 2019 Oct 15.
3
Optical coherence tomography angiography findings in cystoid macular degeneration associated with central serous chorioretinopathy.与中心性浆液性脉络膜视网膜病变相关的囊样黄斑变性的光相干断层扫描血管造影表现。
Br J Ophthalmol. 2019 Nov;103(11):1615-1618. doi: 10.1136/bjophthalmol-2018-313048. Epub 2019 Jan 2.
4
OCT Risk Factors for 3-Year Development of Macular Complications in Eyes With "Resolved" Chronic Central Serous Chorioretinopathy.OCT 风险因素与“缓解”的慢性中心性浆液性脉络膜视网膜病变眼 3 年黄斑并发症的发展。
Am J Ophthalmol. 2021 Mar;223:129-139. doi: 10.1016/j.ajo.2020.10.011. Epub 2020 Oct 22.
5
Long-term Visual Outcomes and Causes of Vision Loss in Chronic Central Serous Chorioretinopathy.慢性中心性浆液性脉络膜视网膜病变的长期视力结果和致盲原因。
Ophthalmology. 2019 Apr;126(4):576-588. doi: 10.1016/j.ophtha.2018.12.048. Epub 2019 Jan 17.
6
Abnormal choroidal flow on optical coherence tomography angiography in central serous chorioretinopathy.脉络膜血流异常在中心性浆液性脉络膜视网膜病变的光学相干断层扫描血管造影中的表现。
Clin Exp Ophthalmol. 2019 May;47(4):505-512. doi: 10.1111/ceo.13454. Epub 2019 Feb 17.
7
Clinical Features of Central Serous Chorioretinopathy With Type 1 Choroidal Neovascularization.具有 1 型脉络膜新生血管的中心性浆液性脉络膜视网膜病变的临床特征。
Am J Ophthalmol. 2018 Sep;193:80-86. doi: 10.1016/j.ajo.2018.06.009. Epub 2018 Jun 27.
8
FLAT IRREGULAR PIGMENT EPITHELIUM DETACHMENT IN CENTRAL SEROUS CHORIORETINOPATHY: A Form of Pachychoroid Neovasculopathy?中浆:平坦型不规则色素上皮脱离是一种厚脉络膜新生血管病变?
Retina. 2020 Sep;40(9):1724-1733. doi: 10.1097/IAE.0000000000002662.
9
Effect of Acetazolamide on Choroidal Morphology in Central Serous Chorioretinopathy.乙酰唑胺对中心性浆液性脉络膜视网膜病变脉络膜形态的影响。
Korean J Ophthalmol. 2019 Dec;33(6):493-499. doi: 10.3341/kjo.2019.0063.
10
Optical coherence tomography angiography of flat irregular pigment epithelial detachments in central serous chorioretinopathy.中心性浆液性脉络膜视网膜病变中扁平状不规则色素上皮脱离的光相干断层扫描血管造影。
Br J Ophthalmol. 2021 Feb;105(2):233-238. doi: 10.1136/bjophthalmol-2019-315318. Epub 2020 Apr 7.

引用本文的文献

1
Incidence of recurrence and development of polypoidal lesions following half-dose and two-thirds dose photodynamic therapy for pachychoroid neovasculopathy.半剂量和三分之二剂量光动力疗法治疗厚脉络膜新生血管病变后息肉样病变的复发率和发生率
Sci Rep. 2025 May 30;15(1):18975. doi: 10.1038/s41598-025-03782-2.
2
Choroidal Response to Intravitreal Bevacizumab Injections in Treatment-Naïve Macular Neovascularization Secondary to Chronic Central Serous Chorioretinopathy.初治慢性中心性浆液性脉络膜视网膜病变继发黄斑新生血管时玻璃体内注射贝伐单抗后的脉络膜反应
Biomedicines. 2024 Dec 3;12(12):2760. doi: 10.3390/biomedicines12122760.
3
The role of inflammation in central serous chorioretinopathy: From mechanisms to therapeutic prospects.
炎症在中心性浆液性脉络膜视网膜病变中的作用:从机制到治疗前景
Front Pharmacol. 2024 May 21;15:1200492. doi: 10.3389/fphar.2024.1200492. eCollection 2024.
4
Three-Year Follow-Up Detecting Choroidal Neovascularization with Swept Source Optical Coherence Tomography Angiography (SS-OCTA) after Successful Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.慢性中心性浆液性脉络膜视网膜病变半量光动力疗法成功后,使用扫频源光学相干断层扫描血管造影(SS-OCTA)进行三年随访以检测脉络膜新生血管形成
Diagnostics (Basel). 2023 Aug 29;13(17):2792. doi: 10.3390/diagnostics13172792.
5
Two-year outcome of half-time photodynamic therapy for chronic central serous chorioretinopathy with and without choroidal neovascularization.伴有和不伴有脉络膜新生血管的慢性中心性浆液性脉络膜视网膜病变半量光动力疗法的两年疗效。
PLoS One. 2023 May 2;18(5):e0284979. doi: 10.1371/journal.pone.0284979. eCollection 2023.
6
Predictive factors for outcomes of half-dose photodynamic therapy combined with aflibercept for pachychoroid neovasculopathy.半剂量光动力疗法联合阿柏西普治疗厚脉络膜新生血管病变的疗效预测因素。
Graefes Arch Clin Exp Ophthalmol. 2023 Aug;261(8):2235-2243. doi: 10.1007/s00417-023-06030-3. Epub 2023 Mar 8.
7
Type one macular neovascularization in central serous chorioretinopathy: Short-term response to anti-vascular endothelial growth factor therapy.中心性浆液性脉络膜视网膜病变中 1 型黄斑新生血管:抗血管内皮生长因子治疗的短期反应。
Eye (Lond). 2022 Oct;36(10):1945-1950. doi: 10.1038/s41433-021-01778-6. Epub 2021 Sep 28.
8
Applications of Multimodal Imaging in Central Serous Chorioretinopathy Evaluation.多模态成像在中心性浆液性脉络膜视网膜病变评估中的应用。
J Ophthalmol. 2021 Jul 24;2021:9929864. doi: 10.1155/2021/9929864. eCollection 2021.
9
3-year follow-up of half-dose verteporfin photodynamic therapy for central serous chorioretinopathy with OCT-angiography detected choroidal neovascularization.OCT-angiography 检测脉络膜新生血管的中渗经半剂量维替泊芬光动力疗法 3 年随访
Sci Rep. 2021 Jun 24;11(1):13286. doi: 10.1038/s41598-021-92693-z.